Skip to main content
Log in

Influence of the rt-PA dose (1 mg/kg versus 1.5 mg/kg) and duration of administration on the patency of infarct-related coronary arteries in 81 patients

  • Thrombolysis
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

This open study compared the efficacy and side effects of two dose regimens of intravenous rt-PA initiated before the fifth hour after the onset of myocardial infarction. The first 40 patients (group A) received 1 mg/kg of rt-PA infused over 90 minutes, including a 10-mg initial bolus. The following 41 patients (group B) received 1.5 mg/kg (20-mg initial bolus, 60% over 60 minutes and 40% over 120 minutes). Noninvasive clinical, electrocardiographic, and biochemical parameters of reperfusion were recorded systematically, along with serial measurements of fibrinogen and hemoglobin levels. Coronary arteriography and left ventriculography were performed at the 48th hour or earlier, on an emergency basis, in the absence of signs of reperfusion, or if there were clinical and ECG signs of rethrombosis. Patency of the infarct-related artery (TIMI grades 2 and 3) was achieved in 55% of the group A patients vs. 83% of the group B patients (p<.01). Twelve emergency coronary arteriographies were performed in each group. No significant difference was observed in the ejection fraction (48% in group A vs. 52% in group B). The peak CPK level was similar in both groups, but the peak occurred earlier in group B (p<.001). There was no statistically significant difference between the two dose regimens in terms of reduction in fibrinogen or plasminogen levels. Two deaths occurred in group A vs. one death in group B. No cerebrovascular accidents occurred in either group. Overall, a rt-PA dose of 1.5 mg/kg administered over 180 minutes proved superior in producing patency of the infarct-related artery at approximately the 48th hour to an rt-PA dose of 1 mg/kg administered over 90 minutes, without increasing the incidence of adverse effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. The TIMI Research Group. Immediate versus delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. JAMA 1988;260:2849–2858.

    Google Scholar 

  2. Tebbe U, Tanswell P, Siefried E, et al. Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction. Am J Cardiol 1989;64:448–453.

    Google Scholar 

  3. Neuhaus KL, Tebbe U, Weber AJ. Intravenous recombinant tissue type plasminogen activator and urokinase in acute myocardial infarction: Results of the German Activator Urokinase Study (GAUS). J Am Coll Cardiol 1988;12:581–587.

    Google Scholar 

  4. Lew AS, Cercek B, Lewis BS, et al. Efficacy of a two-hour infusion of 150 mg tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1987;60:1225–1229.

    Google Scholar 

  5. Neuhaus KL, Feuerer W, Tebbe S, et al. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1989;14: 1566–1569.

    Google Scholar 

  6. Topol EJ, George BS, Kereiakes DJ, and the TAMI Study Group. Comparison of two dose regimens of intravenous tissue plasminogen activator for acute myocardial infarction. Am J Cardiol 1988;61:723–728.

    Google Scholar 

  7. Topol EJ, George BS, Kereiakes DJ, and the TAMI Study Group. Randomized controlled trial of intravenous plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989;79:281–286.

    Google Scholar 

  8. Johns JA, Gold HK, Leinbach RE, et al. Prevention of coronary reocclusion and reduction in late coronary stenosis after thrombolytic therapy in patients with acute myocardial infarction. Circulation 1988;78:546–556.

    Google Scholar 

  9. Harrison DG, Ferguson DW, Collins SM, et al. Rethrombosis after reperfusion with streptokinase: Importance of geometry of residual lesions. Circulation 1984;69:991–999.

    Google Scholar 

  10. Schroder R, Vohringer H, Linderer T. Follow-up coronary arterial reperfusion with intravenous streptokinase in relation to residual myocardial infarct artery narrowing. Am J Cardiol 1985;55:313–317.

    Google Scholar 

  11. Verstraete M, Arnold A, Brower RW, et al. Acute coronary thrombolysis with recombinant human tissue type plasminogen activator: Initial patency and influence of maintained infusion on reocclusion rate. Am J Cardiol 1987;60:231–237.

    Google Scholar 

  12. Hsia J, Hamilton WP, Kleiman N, et al. A comparison between heparin and low dose aspirin as adjunction therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990;323:1433–1437.

    Google Scholar 

  13. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987;76:142–154.

    Google Scholar 

  14. Carney R, Brandt T, Daley P, et al. Increased efficacy of rt-PA by more rapid administration: The RAAMI trial (abstract). Circulation 1990;82 (Suppl III: 538).

    Google Scholar 

  15. Magnani B for the PAIMS Investigators. Plasminogen Activator Italian Multicenter Study (PAIMS): Comparison of intravenous recombinant single-chain human tissue-type plasminogen activator rt-PA with intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol 1989; 13:19–26.

    Google Scholar 

  16. European Cooperative Study Group (ECSG). Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. Br Med J 1988;297:1374–1379.

    Google Scholar 

  17. O'Rourke D, Baron D, Keogh A, et al. Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator. Circulation 1988;77:1311–1315.

    Google Scholar 

  18. Mueller HS, Rao AK, Forman SA, and the TIMI Investigators. Thrombolysis in myocardial infarction (TIMI): Comparative studies of coronary reperfusion and systemic fibrinogen with two forms of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1987;10:479–490.

    Google Scholar 

  19. Passamani E, Hodges M, herman M, et al. The thrombolysis in myocardial infarction (TIMI) phase II pilot study: Tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1987;10: 51B-64B.

    Google Scholar 

  20. Smalling RW, Schumacher R, Morris D, et al. Improved infarct-related arterial patency after high-dose, weight-adjusted, rapid infusion of tissue-type plasminogen activator in myocardial infarction: Results of a multicenter randomized trial of two dosage regimens. J Am Coll Cardiol 1990;15:915–921.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gibelin, P., Tiger, F., Moles, V. et al. Influence of the rt-PA dose (1 mg/kg versus 1.5 mg/kg) and duration of administration on the patency of infarct-related coronary arteries in 81 patients. Cardiovasc Drug Ther 6, 373–377 (1992). https://doi.org/10.1007/BF00054184

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00054184

Key Words

Navigation